Lytix Biopharma: Redeye Resumes Coverage
Research Note
2024-04-26
15:08
Through the completion of the equity issue, Lytix receives NOK50m before transaction costs. The issue was almost subscribed to the lower amount, with around 5% going to certain pre-committing shareholders and guarantors.
Richard Ramanius
Disclosures and disclaimers